{"id":"NCT01109316","sponsor":"Eli Lilly and Company","briefTitle":"Insulin Lispro 6 Days Versus Insulin Aspart 6 Days in Pump Use","officialTitle":"An Open-Label, Randomized, Crossover Trial of CSII Reservoir In-use Comparing Insulin Lispro Formulation to Insulin Aspart in Patients With Type 1 Diabetes Mellitus","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-04","primaryCompletion":"2011-08","completion":"2011-08","firstPosted":"2010-04-23","resultsPosted":"2012-10-30","lastUpdate":"2019-03-27"},"enrollment":132,"design":{"allocation":"RANDOMIZED","model":"CROSSOVER","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes Mellitus, Type 1"],"interventions":[{"type":"DRUG","name":"Insulin lispro 2 day reservoir in-use","otherNames":["LY275585","Humalog"]},{"type":"DRUG","name":"Insulin lispro 6 day reservoir in-use","otherNames":["LY275585","Humalog"]},{"type":"DRUG","name":"Insulin aspart 6 day reservoir in-use","otherNames":[]}],"arms":[{"label":"Insulin Lispro 2 Day","type":"ACTIVE_COMPARATOR"},{"label":"Insulin Lispro 6 Day","type":"EXPERIMENTAL"},{"label":"Insulin Aspart 6 Day","type":"ACTIVE_COMPARATOR"}],"summary":"This is a 6-sequence, 3-period (8 weeks each), 3-arm, 24-week crossover study. The purpose of this study is to provide information on the use of insulin lispro in insulin pumps (Continuous Subcutaneous Insulin Infusion \\[CSII\\]) compared to insulin aspart over 6 days of pump reservoir in-use. The study will also compare the in-use characteristics of insulin lispro infused at 6 days with insulin lispro infused at 2 days.","primaryOutcome":{"measure":"Mean of Last Five 7-point Self Monitored Blood Glucose (SMBG) Taken on Day 6 for Insulin Lispro 6D and Day 2 for Insulin Lispro 2D and Day 6 for Insulin Aspart 6D Pump Reservoir In-use","timeFrame":"8 weeks of each treatment","effectByArm":[{"arm":"Insulin Lispro 2 Day","deltaMin":9.03,"sd":2.17},{"arm":"Insulin Lispro 6 Day","deltaMin":9.33,"sd":2.31},{"arm":"Insulin Aspart 6 Day","deltaMin":8.72,"sd":1.82}],"pValues":[{"comp":"OG001 vs OG002","p":null}]},"eligibility":{"minAge":"13 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":18},"locations":{"siteCount":11,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":122},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Oropharyngeal pain","Headache","Nausea"]}}